First American Trust FSB Acquires 2,155 Shares of Johnson & Johnson (NYSE:JNJ)

First American Trust FSB lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 45.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,915 shares of the company's stock after buying an additional 2,155 shares during the period. First American Trust FSB's holdings in Johnson & Johnson were worth $1,000,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the business. MRP Capital Investments LLC raised its stake in shares of Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after buying an additional 65 shares during the period. Werba Rubin Papier Wealth Management grew its stake in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after acquiring an additional 66 shares during the period. Denali Advisors LLC raised its stake in Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after acquiring an additional 67 shares during the period. Sage Mountain Advisors LLC raised its stake in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock valued at $2,106,000 after acquiring an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC boosted its position in Johnson & Johnson by 3.7% during the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock worth $287,000 after purchasing an additional 70 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $2.15 during midday trading on Tuesday, hitting $161.14. The company had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. The company has a market capitalization of $388.32 billion, a PE ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's fifty day moving average price is $157.70 and its 200-day moving average price is $156.14.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on JNJ shares. Citigroup lowered their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Bank of America boosted their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a research note on Wednesday, March 5th. Finally, Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.